Pharmacokinetic Study of Polidocanol Endovenous Microfoam (PEM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01428076
Recruitment Status : Completed
First Posted : September 2, 2011
Results First Posted : March 31, 2014
Last Update Posted : March 6, 2015
Information provided by (Responsible Party):
BTG International Inc.

Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Condition: Varicose Veins
Intervention: Drug: Polidocanol Endovenous Microfoam (PEM)

  Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
Polidocanol 1% polidocanol injectable foam 1% concentration
Polidocanol 2% polidocanol injectable foam 2% concentration

Participant Flow:   Overall Study
    Polidocanol 1%   Polidocanol 2%
STARTED   9   12 
COMPLETED   9   11 
Adverse Event                0                1 

  Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Safety population

Reporting Groups
Polidocanol 1% polidocanol injectable foam 1% concentration
Polidocanol 2% polidocanol intravenous foam 2% concentration
Total Total of all reporting groups

Baseline Measures
   Polidocanol 1%   Polidocanol 2%   Total 
Overall Participants Analyzed 
[Units: Participants]
 9   12   21 
[Units: Years]
Mean (Standard Deviation)
 54.0  (9.62)   49.9  (11.4)   51.7  (10.6) 
[Units: Participants]
Female   6   6   12 
Male   3   6   9 
Race (NIH/OMB) 
[Units: Participants]
American Indian or Alaska Native   0   0   0 
Asian   0   0   0 
Native Hawaiian or Other Pacific Islander   0   0   0 
Black or African American   0   0   0 
White   9   12   21 
More than one race   0   0   0 
Unknown or Not Reported   0   0   0 
[Units: Kg/m^2]
Mean (Standard Deviation)
 27.1  (2.52)   27.1  (5.19)   27.1  (4.16) 

  Outcome Measures

1.  Primary:   Weight-adjusted Polidocanol Cmax (Serum)   [ Time Frame: pharmacokinetics measured- predose, 1, 4, 5, 7, 9, 11, 14, 15, 17, 20, 25, 30 minutes post dose, 1, 2, 3, 4, 5, 6, 8 hours post dose ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

Results Point of Contact:  
Name/Title: David Wright MB FRCS
Organization: BTG International Inc.
phone: 610-278-1660

Responsible Party: BTG International Inc. Identifier: NCT01428076     History of Changes
Other Study ID Numbers: VAP.VV008
First Submitted: August 30, 2011
First Posted: September 2, 2011
Results First Submitted: January 15, 2014
Results First Posted: March 31, 2014
Last Update Posted: March 6, 2015